Matt Outten

Matt Outten is currently the Chief Commercial Officer at BridgeBio, a position they have held for 3 years and 5 months. Prior to joining BridgeBio, Matt was the Chief Commercial Officer at QED Therapeutics, a BridgeBio company. At QED, Matt was singularly focused on the development of their investigational candidate, infigratinib. Infigratinib is a first-in-class, selective, tyrosine kinase inhibitor with promising early clinical data in patients with previously treated, FGFR-driven cholangiocarcinoma and metastatic urothelial carcinoma, as well as preclinical studies in achondroplasia. Future studies will investigate infigratinib for additional FGFR-driven tumor types and rare disorders.

Matt Outten has a Master of Liberal Arts in Extension Studies from Harvard University, an MBA from the University of Delaware, and a degree in Psychology from Hamilton College. Matt also attended The Hill School.